[go: up one dir, main page]

PL3981437T3 - Szczepionki z kwasem nukleinowym - Google Patents

Szczepionki z kwasem nukleinowym

Info

Publication number
PL3981437T3
PL3981437T3 PL21191353.8T PL21191353T PL3981437T3 PL 3981437 T3 PL3981437 T3 PL 3981437T3 PL 21191353 T PL21191353 T PL 21191353T PL 3981437 T3 PL3981437 T3 PL 3981437T3
Authority
PL
Poland
Prior art keywords
nucleic acid
acid vaccines
vaccines
nucleic
acid
Prior art date
Application number
PL21191353.8T
Other languages
English (en)
Inventor
Giuseppe Ciaramella
Axel Bouchon
Eric Yi-Chun Huang
Original Assignee
Modernatx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54333225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3981437(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Modernatx, Inc. filed Critical Modernatx, Inc.
Publication of PL3981437T3 publication Critical patent/PL3981437T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL21191353.8T 2014-04-23 2015-04-23 Szczepionki z kwasem nukleinowym PL3981437T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461983250P 2014-04-23 2014-04-23
US201462088994P 2014-12-08 2014-12-08

Publications (1)

Publication Number Publication Date
PL3981437T3 true PL3981437T3 (pl) 2025-02-24

Family

ID=54333225

Family Applications (3)

Application Number Title Priority Date Filing Date
PL21191353.8T PL3981437T3 (pl) 2014-04-23 2015-04-23 Szczepionki z kwasem nukleinowym
PL21195046.4T PL4023249T3 (pl) 2014-04-23 2015-04-23 Szczepionki z kwasem nukleinowym
PL15783606T PL3134131T3 (pl) 2014-04-23 2015-04-23 Szczepionki z kwasem nukleinowym

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL21195046.4T PL4023249T3 (pl) 2014-04-23 2015-04-23 Szczepionki z kwasem nukleinowym
PL15783606T PL3134131T3 (pl) 2014-04-23 2015-04-23 Szczepionki z kwasem nukleinowym

Country Status (23)

Country Link
US (10) US10022435B2 (pl)
EP (4) EP3981437B1 (pl)
JP (3) JP6881813B2 (pl)
CN (1) CN106659803A (pl)
AU (3) AU2015249553B2 (pl)
BR (1) BR112016024644A2 (pl)
CA (2) CA3177878A1 (pl)
CY (1) CY1125084T1 (pl)
DK (3) DK3134131T3 (pl)
ES (3) ES3009962T3 (pl)
FI (2) FI4023249T3 (pl)
HR (3) HRP20241732T1 (pl)
HU (3) HUE069802T2 (pl)
LT (3) LT3134131T (pl)
MA (2) MA59052B1 (pl)
PL (3) PL3981437T3 (pl)
PT (3) PT3134131T (pl)
RS (3) RS63050B1 (pl)
RU (2) RU2021109685A (pl)
SG (2) SG10201912038TA (pl)
SI (3) SI3134131T1 (pl)
SM (3) SMT202500053T1 (pl)
WO (1) WO2015164674A1 (pl)

Families Citing this family (304)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
RU2670745C9 (ru) 2011-05-24 2018-12-13 Бионтех Рна Фармасьютикалс Гмбх Индивидуализированные противоопухолевые вакцины
BR112013031553A2 (pt) 2011-06-08 2020-11-10 Shire Human Genetic Therapies, Inc. composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
BR112014007852B1 (pt) 2011-10-03 2021-11-03 Moderna Therapeutics, Inc Polinucleotídeo isolado modificado e composição farmacêutica
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
HK1206779A1 (en) 2012-04-02 2016-01-15 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
CA2876155C (en) 2012-06-08 2022-12-13 Ethris Gmbh Pulmonary delivery of mrna to non-lung target cells
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
WO2014153052A2 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Cftr mrna compositions and related methods and uses
EP4446413A3 (en) 2013-03-14 2024-12-18 Translate Bio, Inc. Methods for purification of messenger rna
HUE055044T2 (hu) 2013-03-14 2021-10-28 Translate Bio Inc MRNS-kódolt ellenanyagok bejuttatására szolgáló eljárások és készítmények
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
ES2795249T3 (es) 2013-03-15 2020-11-23 Translate Bio Inc Mejora sinérgica de la administración de ácidos nucleicos a través de formulaciones mezcladas
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2014198004A1 (en) * 2013-06-11 2014-12-18 Biocartis Nv Biomolecule drying process for long-term storage
PT3019619T (pt) 2013-07-11 2021-11-11 Modernatx Inc Composições que compreendem polinucleótidos sintéticos que codificam proteínas relacionadas com crispr e sgarn sintéticos e métodos de utilização
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052511A4 (en) * 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
CN105658242A (zh) 2013-10-22 2016-06-08 夏尔人类遗传性治疗公司 用于苯丙酮尿症的mrna疗法
EP4036241A1 (en) 2013-10-22 2022-08-03 Translate Bio, Inc. Cns delivery of mrna and uses thereof
ES2707966T3 (es) 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
PL3981437T3 (pl) 2014-04-23 2025-02-24 Modernatx, Inc. Szczepionki z kwasem nukleinowym
CN106164248B (zh) 2014-04-25 2019-10-15 川斯勒佰尔公司 信使rna的纯化方法
EP3157573A4 (en) 2014-06-19 2018-02-21 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
EP3160938B1 (en) 2014-06-25 2020-09-16 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3169335B8 (en) 2014-07-16 2019-10-09 ModernaTX, Inc. Circular polynucleotides
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2016176330A1 (en) * 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
AU2016285852B2 (en) 2015-06-29 2020-12-17 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
ES2937963T3 (es) * 2015-07-21 2023-04-03 Modernatx Inc Vacunas de enfermedad infecciosa
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US20190008887A1 (en) * 2015-07-30 2019-01-10 ModernaTX Inc. Multimeric mrna
HK1256498A1 (zh) 2015-07-30 2019-09-27 Modernatx, Inc. 聚肽表位 rna
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
AU2016324463B2 (en) 2015-09-17 2022-10-27 Modernatx, Inc. Polynucleotides containing a stabilizing tail region
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
WO2017066573A1 (en) 2015-10-14 2017-04-20 Shire Human Genetic Therapies, Inc. Modification of rna-related enzymes for enhanced production
WO2017070620A2 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Broad spectrum influenza virus vaccine
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
MA46080A (fr) 2015-10-22 2019-07-10 Modernatx Inc Vaccins à base d'acide nucléique contre le virus varicelle-zona (vzv)
MA46316A (fr) 2015-10-22 2021-03-24 Modernatx Inc Vaccin contre le cytomégalovirus humain
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
WO2017070623A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Herpes simplex virus vaccine
EP4349404A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
FI3368507T3 (fi) 2015-10-28 2023-03-21 Acuitas Therapeutics Inc Uusia lipidejä ja lipidinanopartikkeliformulaatioita nukleiinihappojen annostelemiseksi
CN108699561B (zh) * 2015-11-19 2022-09-13 创嘉生物科技有限公司 重组乳酸菌及其在口服通用流感疫苗中的用途
LT3386484T (lt) * 2015-12-10 2022-06-10 Modernatx, Inc. Gydomųjų medžiagų sudėtis ir pristatymo metodai
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
WO2017152146A2 (en) 2016-03-03 2017-09-08 Duke University Compositions and methods for inducing hiv-1 antibodies
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
CA3020343A1 (en) 2016-04-08 2017-10-12 Translate Bio, Inc. Multimeric coding nucleic acid and uses thereof
CN116077439A (zh) 2016-04-29 2023-05-09 西奈山伊坎医学院 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
EP4233898A3 (en) * 2016-05-04 2023-11-01 CureVac SE Influenza mrna vaccines
EP4137509A1 (en) 2016-05-18 2023-02-22 ModernaTX, Inc. Combinations of mrnas encoding immune modulating polypeptides and uses thereof
JP7088911B2 (ja) 2016-05-18 2022-06-21 モデルナティエックス インコーポレイテッド リラキシンをコードするポリヌクレオチド
WO2017201342A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
SG11201809381XA (en) 2016-05-18 2018-12-28 Modernatx Inc Polynucleotides encoding interleukin-12 (il12) and uses thereof
JP7114485B2 (ja) * 2016-05-18 2022-08-08 モデルナティエックス インコーポレイテッド ファブリー病の治療のためのα－ガラクトシダーゼＡをコードするポリヌクレオチド
MA45037A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polythérapie à base d'arnm pour le traitement du cancer
US10835583B2 (en) 2016-06-13 2020-11-17 Translate Bio, Inc. Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency
MX2019000205A (es) 2016-07-07 2019-09-23 Rubius Therapeutics Inc Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
CN115537372A (zh) * 2016-07-13 2022-12-30 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
JP2019528312A (ja) * 2016-08-07 2019-10-10 ノバルティス アーゲー ｍＲＮＡ媒介性の免疫化方法
JP2019528284A (ja) * 2016-08-17 2019-10-10 ファクター バイオサイエンス インコーポレイテッド 核酸産物およびその投与方法
AU2017326423B2 (en) 2016-09-14 2023-11-09 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
EP3519428A4 (en) 2016-10-03 2020-07-08 Duke University METHODS OF IDENTIFYING IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS
WO2018075830A1 (en) 2016-10-19 2018-04-26 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
KR20190093816A (ko) * 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
CA3042015A1 (en) * 2016-10-26 2018-05-03 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
WO2018081638A1 (en) * 2016-10-27 2018-05-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
WO2018107088A2 (en) * 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
US11141476B2 (en) 2016-12-23 2021-10-12 Curevac Ag MERS coronavirus vaccine
US11241490B2 (en) 2017-01-11 2022-02-08 The Trustees Of The University Of Pennsylvania Nucleoside-modified RNA for inducing an immune response against zika virus
SG11201906969PA (en) 2017-02-01 2019-08-27 Modernatx Inc Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
CN110505877A (zh) 2017-02-01 2019-11-26 摩登纳特斯有限公司 Rna癌症疫苗
WO2018151816A1 (en) 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
CN107300583A (zh) * 2017-04-18 2017-10-27 武汉博沃生物科技有限公司 疫苗中蔗糖含量的检测方法及其应用
US20200054737A1 (en) * 2017-04-26 2020-02-20 Modema TX, Inc. Herpes simplex virus vaccine
JP7464954B2 (ja) * 2017-04-27 2024-04-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｃ型肝炎ウイルスに対するヌクレオシド修飾ｍＲＮＡ－脂質ナノ粒子系統ワクチン
IL301115A (en) 2017-04-28 2023-05-01 Acuitas Therapeutics Inc Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
AU2018275267B2 (en) 2017-06-02 2024-10-10 Matthew Kerner Phenotypically wild-type and genetically attenuated viruses
US11154607B2 (en) * 2017-06-02 2021-10-26 Laura SHACKELTON Genetically attenuated nucleic acid vaccine
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
CA3073020A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036000A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP3668522B1 (en) * 2017-08-18 2024-09-11 ModernaTX, Inc. Efficacious mrna vaccines
EP3668971B8 (en) 2017-08-18 2024-05-29 ModernaTX, Inc. Rna polymerase variants
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
US11517591B2 (en) 2017-09-01 2022-12-06 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
KR102822306B1 (ko) * 2017-09-29 2025-06-19 인텔리아 테라퓨틱스, 인크. 게놈 편집을 위한 폴리뉴클레오티드, 조성물 및 방법
WO2019070730A1 (en) 2017-10-02 2019-04-11 Duke University MOSAIC ENVELOPES OF HIV-1 TO INDUCE ADCC RESPONSES
MX2020003995A (es) * 2017-10-19 2020-07-22 Curevac Ag Nuevas moleculas de acido nucleico artificiales.
GB201718660D0 (en) * 2017-11-10 2017-12-27 Ucl Business Plc Improved liposome for mRNA delivery to cells
JP2021504445A (ja) * 2017-11-21 2021-02-15 モデルナティーエックス， インコーポレイテッド エプスタイン−バーウイルスワクチン
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
IL275205B2 (en) 2017-12-15 2025-03-01 Flagship Pioneering Innovations Vi Llc Preparations containing circular polyribonucleotides and uses thereof
US11167043B2 (en) 2017-12-20 2021-11-09 Translate Bio, Inc. Composition and methods for treatment of ornithine transcarbamylase deficiency
US12139617B2 (en) 2017-12-22 2024-11-12 North Carolina State University Polymeric fluorophores, compositions comprising the same, and methods of preparing and using the same
US20210069310A1 (en) * 2018-01-05 2021-03-11 Rolf Jonas Andreas NILSSON Endogenous tumor-derived circular rna and proteins thereof for use as vaccine
JP7547201B2 (ja) 2018-01-12 2024-09-09 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインを標的とするアンチセンスオリゴヌクレオチドおよびその使用
MY203356A (en) 2018-01-12 2024-06-25 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof
EP3746090A4 (en) * 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
JP2021514391A (ja) * 2018-02-15 2021-06-10 アイコン ジェネティクス ゲーエムベーハー ノロウイルスに対する免疫応答を生成するための免疫原性組成物及びワクチン
CN108424881B (zh) * 2018-03-23 2021-07-27 中国食品药品检定研究院 一株肠道病毒68型及其在制备ev-d68型感染动物中的应用
TWI682779B (zh) * 2018-04-03 2020-01-21 林淑卿 豬疾病疫苗用佐劑及其製備方法
CN108324941A (zh) * 2018-04-03 2018-07-27 林淑卿 猪疾病疫苗用佐剂及其制备方法
US11679159B2 (en) * 2018-04-29 2023-06-20 Precision NanoSystems ULC Compositions for transfecting resistant cell types
EP3794008A1 (en) * 2018-05-16 2021-03-24 Translate Bio, Inc. Ribose cationic lipids
CN108795935B (zh) * 2018-05-23 2022-06-21 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 日本血吸虫SjELAV-like 1基因的siRNA及其应用
IL319091A (en) 2018-06-06 2025-04-01 Massachusetts Inst Technology Circular RNA for translation in eukaryotic cells
US12357580B2 (en) 2018-06-19 2025-07-15 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
AU2019299216A1 (en) 2018-07-03 2021-01-07 Fennec Pharmaceuticals, Inc. Anhydrous sodium thiosulfate and formulations thereof
KR20210060480A (ko) 2018-08-24 2021-05-26 트랜슬레이트 바이오 인코포레이티드 전령 rna의 정제 방법
GB2617430B (en) 2018-09-04 2023-12-27 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
GB2617429B (en) * 2018-09-04 2023-12-27 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
JP7640452B2 (ja) * 2018-09-19 2025-03-05 モデルナティエックス インコーポレイテッド 高純度ｐｅｇ脂質及びそれらの使用
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
CA3113651A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
IL322436A (en) 2018-09-21 2025-09-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
US20210322575A1 (en) 2018-09-28 2021-10-21 Nutcracker Therapeutics, Inc. Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
WO2020072162A1 (en) * 2018-10-01 2020-04-09 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies
EP3860650A4 (en) 2018-10-01 2022-06-29 Duke University Hiv-1 envelope stabilizing mutations
KR20210093232A (ko) * 2018-10-09 2021-07-27 더 유니버시티 오브 브리티시 콜롬비아 유기용매와 세제가 없는 형질감염 적격 소포를 포함하는 조성물과 시스템 및 관련 방법
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3120647A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
US12042527B2 (en) 2019-01-08 2024-07-23 Modernatx, Inc. Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN113474328B (zh) 2019-01-11 2025-07-11 爱康泰生治疗公司 用于脂质纳米颗粒递送活性剂的脂质
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
CN113795579A (zh) 2019-02-20 2021-12-14 摩登纳特斯有限公司 用于共转录加帽的rna聚合酶变体
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
EP3938507A4 (en) 2019-03-11 2023-02-22 ModernaTX, Inc. PROCEDURE FOR IN VITRO FED BATCH TRANSCRIPTION
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
WO2020198403A2 (en) 2019-03-25 2020-10-01 Flagship Pioneering Innovations Vi, Llc Compositions comprising modified circular polyribonucleotides and uses thereof
CN109880835B (zh) * 2019-03-28 2022-03-25 扬州大学 重组h9n2禽流感病毒株、其制备方法、禽流感疫苗及其应用
CN114040782A (zh) * 2019-04-30 2022-02-11 威斯康星州医药大学股份有限公司 跨鼓膜递送平台及其用途
EP3972653A1 (en) 2019-05-22 2022-03-30 Massachusetts Institute of Technology Circular rna compositions and methods
US20220313815A1 (en) 2019-06-20 2022-10-06 Janssen Sciences Ireland Unlimited Company Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof
WO2021050986A1 (en) * 2019-09-11 2021-03-18 Modernatx, Inc. Lnp-formulated mrna therapeutics and use thereof for treating human subjects
US12018289B2 (en) 2019-11-18 2024-06-25 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
CN110897032B (zh) * 2019-11-19 2025-10-14 华南理工大学 一种发酵饲料蛋白及其制备方法与应用
WO2021113777A2 (en) 2019-12-04 2021-06-10 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2021118976A1 (en) 2019-12-09 2021-06-17 University Of Georgia Research Foundation, Inc. M. tuberculosis ag85 proteins and methods of use
US20230062603A1 (en) * 2020-01-07 2023-03-02 Translate Bio Ma, Inc. Formulations for delivery of oligonucleotides to lung cells
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
JP7438604B2 (ja) * 2020-02-07 2024-02-27 モデルナティエックス インコーポレイテッド ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン
EP4103228A1 (en) 2020-02-13 2022-12-21 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
WO2021160881A1 (en) * 2020-02-14 2021-08-19 Etherna Immunotherapies Nv Intranasal mrna vaccines
CN111378785A (zh) * 2020-03-12 2020-07-07 仁宽(上海)生物科技有限公司 用于核酸诊断新型冠状病毒2019-nCov的假病毒标准品及其应用
GB2605538B (en) 2020-03-23 2024-06-26 Hdt Bio Corp Compositions and methods for delivery of RNA
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
EP4132478A1 (en) 2020-04-09 2023-02-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
KR20230009489A (ko) 2020-05-11 2023-01-17 얀센 파마슈티칼즈, 인코포레이티드 안정화된 코로나 바이러스 스파이크 단백질을 암호화하는 rna 레플리콘
CN111647557A (zh) * 2020-05-18 2020-09-11 中国人民解放军第四军医大学 一种表面偶联s蛋白的外泌体及其制备方法和应用
CN113679701B (zh) * 2020-05-18 2024-04-30 中国科学院上海药物研究所 邻苯三酚及其衍生物作为共价配体反应弹头的用途
JP2023527309A (ja) * 2020-05-19 2023-06-28 オルナ セラピューティクス インコーポレイテッド 環状ｒｎａ組成物及び方法
IL298362A (en) * 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Coronavirus antigen compositions and their uses
BR112022024248A2 (pt) * 2020-05-29 2023-10-10 CureVac SE Vacinas de combinação à base de ácido nucleico
WO2021251453A1 (ja) * 2020-06-11 2021-12-16 第一三共株式会社 核酸脂質粒子ワクチン
CN111714621B (zh) * 2020-06-29 2021-04-27 中国科学院昆明动物研究所 转铁蛋白、转铁蛋白受体及其抗体在制备抗SARS-CoV-2病毒的药物中的应用
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4179112A4 (en) 2020-07-13 2024-11-20 The Board of Trustees of the Leland Stanford Junior University Systems and methods to assess rna stability
EP4182297B1 (en) 2020-07-16 2025-09-03 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
KR20230083266A (ko) * 2020-07-31 2023-06-09 콤바인드 테라퓨틱스, 인코포레이션 개선된 백신접종을 위한 조성물 및 방법
US20220031836A1 (en) * 2020-08-03 2022-02-03 Avalon GloboCare Corp. Emulsomes comprising s-layer fusion proteins and methods of use thereof
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022047427A2 (en) 2020-08-31 2022-03-03 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for producing rna constructs with increased translation and stability
US12458604B2 (en) 2020-10-14 2025-11-04 The Trustees Of The University Of Pennsylvania Methods of lipid nanoparticle manufacture and compositions derived therefrom
WO2022091119A1 (en) * 2020-10-26 2022-05-05 Gunjan Kumar A pharmaceutical kit comprising copper sulfate and ascorbic acid
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
CN112358545B (zh) * 2020-11-10 2022-03-01 中国农业大学 鸽毛滴虫与白色念珠菌二联卵黄抗体粉的制备方法及应用
WO2022108937A2 (en) * 2020-11-17 2022-05-27 Phosphorex, Inc. Novel drug delivery composition and process for blood-brain barrier crossing
EP4255495A4 (en) 2020-12-03 2025-10-08 Battelle Memorial Institute COMPOSITIONS OF POLYMERIC NANOPARTICLES AND DNA NANOSTRUCTURES AND METHODS FOR NON-VIRAL DELIVERY
GB202019916D0 (en) * 2020-12-16 2021-01-27 Imperial College Innovations Ltd RNA vaccine
CA3205569A1 (en) 2020-12-22 2022-06-30 CureVac SE Rna vaccine against sars-cov-2 variants
EP4267181A4 (en) * 2020-12-23 2024-11-20 Daykin Molecular Systems, LLC NUCLEIC ACID STABILIZATION SOLUTION FOR VACCINES, THERAPY, DIAGNOSIS, STORAGE AND TRANSPORT
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
WO2022155173A1 (en) * 2021-01-13 2022-07-21 University Of Maryland, College Park Methods and platforms for eliciting an immune response in the treatment of cancer and compositions and vaccines relating thereto
AU2022208057A1 (en) * 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
US20240165045A1 (en) * 2021-03-08 2024-05-23 Board Of Regents, The University Of Texas System Dry powder formulations of nucleic acid lipid nanoparticles
IL306006A (en) 2021-03-19 2023-11-01 Trained Therapeutix Discovery Inc Compounds for controlling trained immunity, and methods of use thereof
US11260113B1 (en) 2021-03-26 2022-03-01 King Abdulaziz University NK-lysin peptide compositions and methods for their use as antimicrobial/antiviral agents
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2022228827A1 (en) 2021-04-26 2022-11-03 Institut Pasteur Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
CN117320746A (zh) 2021-05-19 2023-12-29 国立研究开发法人医药基盘·健康·营养研究所 Htlv-1核酸脂质颗粒疫苗
EP4342490A4 (en) 2021-05-19 2025-06-04 Daiichi Sankyo Company, Limited Influenza virus nucleic acid lipid particle vaccine
CN113476598A (zh) * 2021-07-20 2021-10-08 武汉圣润生物科技有限公司 一种新型冠状病毒亚蛋白纳米疫苗及其制备方法和应用
US12251471B2 (en) 2021-07-26 2025-03-18 Oregon State University Inhalable therapeutics
WO2023008881A1 (ko) * 2021-07-29 2023-02-02 주식회사 에스엠엘바이오팜 발현 시스템 및 이를 포함하는 핵산 기반 약학 조성물
US20250134824A1 (en) * 2021-08-16 2025-05-01 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
EP4387597A1 (en) * 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
WO2023048758A1 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Dried nanoparticle compositions
WO2023048760A1 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Rna vaccines against infectious diseases
CA3232725A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Cancer therapy compositions and uses thereof
EP4405372A4 (en) 2021-09-22 2026-01-14 Hdt Bio Corp SARS-CoV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE
AU2022361756A1 (en) * 2021-10-06 2024-05-02 Seqirus Inc. Lipid nanoparticle comprising a nucleic acid-binding protein
IL311855A (en) * 2021-10-08 2024-05-01 Pfizer Immunogenic lnp compositions and methods thereof
WO2023064469A1 (en) 2021-10-13 2023-04-20 Modernatx, Inc. Compositions of mrna-encoded il15 fusion proteins and methods of use thereof
JP2024539512A (ja) 2021-10-22 2024-10-28 セイル バイオメディシンズ インコーポレイテッド Ｍｒｎａワクチン組成物
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
CN118488834A (zh) 2021-11-23 2024-08-13 赛欧生物医药股份有限公司 细菌源性脂质组合物和其用途
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2023104904A2 (en) 2021-12-08 2023-06-15 Genclis The sars-cov-2 and variants use two independent cell receptors to replicate
CN115813848B (zh) * 2021-12-10 2023-08-08 上海臻上医药科技有限公司 微针注射mRNA编码双特异性抗体药物的试剂、方法和应用
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
EP4452282A4 (en) * 2021-12-22 2025-10-29 Terence Francis Mullins SYSTEM AND METHOD FOR ANTIBODY ACTIVATORS IN AN AQUEOUS IODINE SOLUTION
EP4460326A2 (en) * 2022-01-07 2024-11-13 HDT Bio Corp. Compositions and methods for multivalent immune responses
CN114437237B (zh) * 2022-01-12 2023-10-24 黑龙江八一农垦大学 金黄色葡萄球菌trap靶向重组蛋白抗原及其用途
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
CN115304756B (zh) * 2022-01-30 2023-05-09 上海科技大学 一种五元脂质纳米颗粒及其制备方法和应用
JP2025508467A (ja) 2022-02-24 2025-03-26 アイオー バイオテック エーピーエス 癌治療のヌクレオチド送達
KR20250005214A (ko) 2022-04-13 2025-01-09 우니버시타트 아우토노마 데 바르셀로나 클로토 단백질을 발현시키는 유전자 요법을 통한 신경근 질환의 치료
WO2023212696A1 (en) 2022-04-29 2023-11-02 Modernatx, Inc. Lyophilized human cytomegalovirus vaccines
CN116942610A (zh) * 2022-04-29 2023-10-27 北京祥瑞生物制品股份有限公司 一种核酸药物递送系统及其制备方法
CN114591386B (zh) * 2022-05-10 2022-09-09 深圳厚存纳米药业有限公司 一种含尿苷衍生物的纳米粒、核酸纳米复合物及其制备方法和用途
JP2025517508A (ja) 2022-05-25 2025-06-05 キュアバック エスイー 核酸ベースのワクチン
EP4296274A1 (en) 2022-06-23 2023-12-27 Universidade de Santiago de Compostela Peptides for intracellular delivery
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024020453A2 (en) * 2022-07-20 2024-01-25 Hdt Bio Corp. Immune system modulators and uses thereof
DE202023106198U1 (de) 2022-10-28 2024-03-21 CureVac SE Impfstoff auf Nukleinsäurebasis
GB202216449D0 (en) 2022-11-04 2022-12-21 Io Biotech Aps TGF-BETA1 vaccine
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
TW202432572A (zh) 2022-12-29 2024-08-16 大陸商仁景（蘇州）生物科技有限公司 用於預防或治療ｈｐｖ感染相關疾病的多核苷酸分子
AU2024212425A1 (en) 2023-01-27 2025-08-07 Sail Biomedicines, Inc. A modified lipid composition and uses thereof
EP4410316A1 (en) * 2023-02-01 2024-08-07 4basebio UK Ltd Nanoparticles for delivery of nucleic acid cargos
WO2024178305A1 (en) 2023-02-24 2024-08-29 Modernatx, Inc. Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
DE112024001143T5 (de) 2023-03-08 2025-12-18 CureVac SE Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren
EP4680287A1 (en) 2023-03-15 2026-01-21 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
EP4680595A2 (en) 2023-03-15 2026-01-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024200826A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof
EP4687991A1 (en) 2023-03-30 2026-02-11 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
EP4442276A1 (en) 2023-04-07 2024-10-09 Institut Pasteur Combined antibodies against sarbecoviruses and uses thereof
WO2024220712A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2024236458A2 (en) * 2023-05-12 2024-11-21 Seqirus Inc. Vaccine adjuvants
WO2024238881A1 (en) * 2023-05-17 2024-11-21 The Regents Of The University Of Michigan Compositions and methods for preventing and treating candida auris infection
WO2024254518A2 (en) * 2023-06-07 2024-12-12 Nvelop Therapeutics, Inc. Compositions of lipid delivery particles and method of use thereof
WO2025006263A2 (en) * 2023-06-27 2025-01-02 Cz Biohub Sf, Llc Design of universal influenza vaccine candidates via antigen reorientation
WO2025007148A1 (en) * 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
WO2025027116A1 (en) 2023-08-01 2025-02-06 Institut Curie Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase
WO2025049959A2 (en) 2023-09-01 2025-03-06 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
US20250073334A1 (en) * 2023-09-05 2025-03-06 The Regents Of The University Of California Injectable hydrogel for sustained co-delivery of an antigen and an adjuvant, and uses thereof
EP4520345A1 (en) 2023-09-06 2025-03-12 Myneo Nv Product
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025133115A1 (en) 2023-12-21 2025-06-26 Ose Immunotherapeutics Lipid-based nanoparticles comprising il-35
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025153707A1 (en) 2024-01-19 2025-07-24 Spikimm Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025194138A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome
WO2025219454A1 (en) 2024-04-18 2025-10-23 Poltreg S.A. Preproinsulin tolerogenic fragments for treating and monitoring type 1 diabetes
WO2025231407A1 (en) * 2024-05-03 2025-11-06 Nutech Ventures Lipid nanoparticles and methods of making and using
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
CN119424376B (zh) * 2025-01-13 2025-07-25 北京大学 一种可超声靶向的脂质纳米颗粒及其应用

Family Cites Families (482)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0204401A1 (en) 1985-04-09 1986-12-10 Biogen, Inc. Method of improving the yield of polypeptides produced in a host cell by stabilizing mRNA
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
EP1026253B2 (en) 1989-03-21 2012-12-19 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
FR2676072B1 (fr) 1991-05-03 1994-11-18 Transgene Sa Vecteur de delivrance d'arn.
EP0802980A1 (en) 1994-06-02 1997-10-29 Chiron Corporation Nucleic acid immunization using a virus-based infection/transfection system
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5824497A (en) 1995-02-10 1998-10-20 Mcmaster University High efficiency translation of mRNA molecules
US6111095A (en) 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
JP2000516445A (ja) 1996-06-21 2000-12-12 メルク エンド カンパニー インコーポレーテッド 合成遺伝子を含むワクチン
US5939262A (en) 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US5989911A (en) 1997-05-09 1999-11-23 University Of Massachusetts Site-specific synthesis of pseudouridine in RNA
AU9319398A (en) 1997-09-19 1999-04-05 Sequitur, Inc. Sense mrna therapy
JP2001519162A (ja) 1997-10-07 2001-10-23 ユニバーシティ・オブ・メリーランド・バイオテクノロジー・インスティチュート 動物細胞にｒｎａを導入して発現させる方法
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
US20090017533A1 (en) 1998-09-29 2009-01-15 Shire Human Genetic Therapies, Inc., A Delaware Corporation Optimized messenger rna
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
CA2364921A1 (en) 1999-02-22 2000-08-31 European Molecular Biology Laboratory Translation system
EP1165798A2 (en) 1999-03-29 2002-01-02 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
ES2238799T3 (es) 1999-09-09 2005-09-01 Curevac Gmbh Transferencia de arn-m.
WO2002064799A2 (en) 1999-09-28 2002-08-22 Transkaryotic Therapies, Inc. Optimized messenger rna
WO2001023002A1 (en) 1999-09-30 2001-04-05 National Jewish Medical And Research Center Method for inhibition of pathogenic microorganisms
AU2001275423B2 (en) 2000-06-09 2007-01-11 Regulon, Inc. Encapsulation of polynucleotides and drugs into targeted liposomes
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
WO2002046477A2 (en) 2000-12-07 2002-06-13 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10109897A1 (de) 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
EP1383556B9 (de) 2001-04-21 2008-03-19 Curevac GmbH INJEKTIONSGERÄT FÜR mRNA APPLIKATION
ES2340499T3 (es) 2001-06-05 2010-06-04 Curevac Gmbh Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
WO2003059381A2 (en) 2002-01-18 2003-07-24 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
EP2338478B1 (en) 2002-06-28 2014-07-23 Protiva Biotherapeutics Inc. Method for producing liposomes
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
AR040575A1 (es) 2002-07-16 2005-04-13 Advisys Inc Plasmidos sinteticos optimizados en codones de expresion en mamiferos
US20040167090A1 (en) 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
AU2004279362B2 (en) 2003-09-15 2011-03-17 Genvec, Inc. HIV vaccines based on ENV of multiple clades of HIV
TW200515917A (en) 2003-09-15 2005-05-16 Us Government Methods and compositions for the generation of a protective immune response against SARS-COV
US20050065114A1 (en) 2003-09-23 2005-03-24 Jean-Claude Yvin Therapeutical treatment with oligo-beta- (1,3) -glucans, drugs used in said treatment
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
EP1766094A4 (en) * 2004-05-18 2009-11-25 Vical Inc FLUID VIRUS VACCINE COMPOSITION AND USE METHOD
WO2005120152A2 (en) 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
BRPI0513390A (pt) 2004-07-16 2008-05-06 Us Gov Health & Human Serv vacinas contra aids contendo construções de ácido nucléico cmv/r
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
US8663599B1 (en) 2004-10-05 2014-03-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
EP1846443A4 (en) 2005-01-07 2008-07-23 Glaxo Group Ltd NEW USE
CA2598884A1 (en) 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
EP4174179B1 (en) 2005-08-23 2025-05-07 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
US20120021042A1 (en) 2005-09-15 2012-01-26 Steffen Panzner Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
CN101346393B (zh) * 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
US8603457B2 (en) 2005-12-02 2013-12-10 University Of Rochester Nonsense suppression and genetic codon alteration by targeted modification
EP1954252B1 (en) 2005-12-02 2016-02-03 GlaxoSmithKline Biologicals SA Nanoparticles for use in immunogenic compositions
AU2006338210A1 (en) 2005-12-14 2007-08-23 The Board Of Regents Of The University Of Oklahoma RNA virus vaccines and methods
CN101432300A (zh) 2006-01-13 2009-05-13 宾夕法尼亚州立大学托管会 采用密码子优化的il-15的疫苗和免疫治疗剂及其使用方法
DE102006007433A1 (de) 2006-02-17 2007-08-23 Curevac Gmbh Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
EP2295045A1 (en) 2006-07-07 2011-03-16 Aarhus Universitet Nanoparticles for nucleic acid delivery
AU2007275047A1 (en) 2006-07-20 2008-01-24 University Of Washington Compositions and methods for vaccinating against HSV-2
EP2046954A2 (en) 2006-07-31 2009-04-15 Curevac GmbH NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
US20080069821A1 (en) * 2006-08-09 2008-03-20 Medimmune Vaccines, Inc. Influenza Hemagglutinin And Neuraminidase Variants
EA017203B1 (ru) 2006-09-07 2012-10-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
AU2007303205A1 (en) 2006-10-03 2008-04-10 Tekmira Pharmaceuticals Corporation Lipid containing formulations
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
US20090088331A1 (en) * 2006-11-07 2009-04-02 Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Influenza virus nucleic acid microarray and method of use
WO2008068631A2 (en) 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
EP2104739B1 (en) 2006-12-21 2013-06-19 Novozymes Inc. Modified messenger rna stabilizing sequences for expressing genes in bacterial cells
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
CN107011431B (zh) 2007-01-30 2020-11-06 埃皮瓦克斯公司 调节性t细胞表位、组合物及其用途
JP2010519203A (ja) 2007-02-16 2010-06-03 メルク・シャープ・エンド・ドーム・コーポレイション 生物活性分子の活性を強化するための組成物及び方法
EP2120876B1 (en) 2007-03-05 2015-03-04 Washington University Nanoparticle delivery systems for membrane-integrating peptides
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US7682789B2 (en) 2007-05-04 2010-03-23 Ventana Medical Systems, Inc. Method for quantifying biomolecules conjugated to a nanoparticle
DK2160464T3 (da) 2007-05-30 2014-08-04 Univ Northwestern Nukleinsyrefunktionaliserede nanopartikler til terapeutiske anvendelser
EP3040082A1 (en) 2007-05-31 2016-07-06 Statens Serum Institut Influenza vaccines
US20090042825A1 (en) 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
US20110086904A1 (en) 2007-09-17 2011-04-14 The Trustees Of The University Of Pennsylvania GENERATION OF HYPERSTABLE mRNAs
EP2042193A1 (en) 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
US8470560B2 (en) 2007-10-03 2013-06-25 The United States Of America As Represented By The Secretary Of The Army CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
AU2008314647B2 (en) 2007-10-12 2013-03-21 Massachusetts Institute Of Technology Vaccine nanotechnology
US8470771B2 (en) 2007-11-14 2013-06-25 Institute Of Microbiology, Chinese Academy Of Sciences Method and medicament for inhibiting the infection of influenza virus
US8081186B2 (en) 2007-11-16 2011-12-20 Microsoft Corporation Spatial exploration field of view preview mechanism
KR101483715B1 (ko) 2008-01-31 2015-01-19 큐어백 게엠바하 면역증강제／애주번트인 화학식（ＮｕＧｌＸｍＧｎＮｖ）ａ를 포함하는 핵산 및 이의 유도체
US20120027813A1 (en) 2008-02-22 2012-02-02 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines for pediatric use
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
US8658354B2 (en) * 2008-03-28 2014-02-25 National University Corporation Hokkaido University Anti-(influenza a virus subtype H5 hemagglutinin) monoclonal antibody
AU2009238175C1 (en) * 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
WO2010009065A2 (en) 2008-07-15 2010-01-21 Novartis Ag Amphipathic peptide compositions
JP5781929B2 (ja) 2008-07-15 2015-09-24 ノバルティス アーゲー 免疫原性の両親媒性ペプチド組成物
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
AU2015210364B2 (en) 2008-10-09 2017-03-09 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
EP2350043B9 (en) 2008-10-09 2014-08-20 TEKMIRA Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
KR20110071017A (ko) 2008-10-16 2011-06-27 마리나 바이오테크, 인크. 유전자 침묵 치료제의 리포좀에 의한 효율적인 전달을 위한 프로세스 및 조성물
MX353900B (es) 2008-11-07 2018-02-01 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
CN111909020A (zh) 2008-11-10 2020-11-10 阿布特斯生物制药公司 用于递送治疗剂的脂质和组合物
WO2010060430A2 (en) 2008-11-28 2010-06-03 Statens Serum Institut Optimized influenza vaccines
US20120101148A1 (en) 2009-01-29 2012-04-26 Alnylam Pharmaceuticals, Inc. lipid formulation
WO2010088927A1 (en) 2009-02-09 2010-08-12 Curevac Gmbh Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
WO2010098861A1 (en) 2009-02-24 2010-09-02 The Scripps Research Institute Reengineering mrna primary structure for enhanced protein production
JP5782602B2 (ja) 2009-03-20 2015-09-24 シーエルエスエヌ ラボラトリーズ、インコーポレイテッド ポリアミン誘導体
WO2010123501A1 (en) 2009-04-22 2010-10-28 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long rna molecules
KR20240015723A (ko) 2009-05-05 2024-02-05 알닐람 파마슈티칼스 인코포레이티드 지질 조성물
CA2764609C (en) 2009-06-10 2018-10-02 Alnylam Pharmaceuticals, Inc. Improved cationic lipid of formula i
CN102458366B (zh) 2009-06-15 2015-02-11 阿尔尼拉姆医药品有限公司 靶向pcsk9基因的脂质配制的dsrna
WO2010148085A1 (en) 2009-06-16 2010-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rna nanoparticles and methods of use
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
CA2766907A1 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
DK2459231T3 (en) 2009-07-31 2016-09-05 Ethris Gmbh RNA with a combination of unmodified and modified nucleotides for protein expression
WO2011017548A1 (en) 2009-08-05 2011-02-10 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
AU2010293059B2 (en) 2009-08-26 2017-03-16 Selecta Biosciences, Inc. Compositions that induce T cell help
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
CN102712935B (zh) 2009-11-04 2017-04-26 不列颠哥伦比亚大学 含有核酸的脂质粒子及相关的方法
ES2666559T3 (es) 2009-12-01 2018-05-07 Translate Bio, Inc. Entrega del mrna para la aumentación de proteínas y enzimas en enfermedades genéticas humanas
KR102171849B1 (ko) 2009-12-07 2020-10-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 세포 리프로그래밍을 위한 정제된 변형 ｒｎａ를 포함하는 ｒｎａ 제제
WO2011075656A1 (en) 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
KR101762466B1 (ko) 2009-12-23 2017-07-27 노파르티스 아게 지질, 지질 조성물 및 이의 사용 방법
US20110184160A1 (en) 2010-01-26 2011-07-28 Weiner David B Nucleic acid molecule encoding consensus influenza a hemagglutinin h1
WO2011106607A2 (en) 2010-02-26 2011-09-01 Juvaris Biotherapeutics, Inc. Subunit vaccines for herpes viruses and methods of use
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
EP2558074B1 (en) 2010-04-08 2018-06-06 The Trustees of Princeton University Preparation of lipid nanoparticles
WO2011130624A2 (en) 2010-04-16 2011-10-20 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143230A1 (en) 2010-05-10 2011-11-17 Alnylam Pharmaceuticals Methods and compositions for delivery of active agents
WO2011141704A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc Novel cyclic cationic lipids and methods of use
WO2011141705A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
EP2387999A1 (en) 2010-05-21 2011-11-23 CureVac GmbH Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
JP2013531634A (ja) 2010-05-24 2013-08-08 メルク・シャープ・エンド・ドーム・コーポレイション オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
EA030813B1 (ru) 2010-05-26 2018-10-31 Селекта Байосайенсиз, Инк Способы генерации антительного иммунного ответа и увеличения местной индукции иммунных цитокинов при использовании синтетических наноносителей, соединенных с адъювантами
EP2575767B1 (en) 2010-06-04 2017-01-04 Sirna Therapeutics, Inc. Novel low molecular weight cationic lipids for oligonucleotide delivery
PT2591114T (pt) 2010-07-06 2016-08-02 Glaxosmithkline Biologicals Sa Imunização de mamíferos de grande porte com doses baixas de arn
LT3243526T (lt) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
EP2590625B1 (en) 2010-07-06 2017-09-20 GlaxoSmithKline Biologicals SA Cationic oil-in-water emulsions
EP2590676B1 (en) 2010-07-06 2016-08-17 GlaxoSmithKline Biologicals SA Virion-like delivery particles for self-replicating rna molecules
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
BR112013000244A2 (pt) 2010-07-06 2016-05-17 Novartis Ag lipossomas com lipídeos apresentando pka vantajoso para administração de rna
ES2558106T3 (es) 2010-07-30 2016-02-02 Curevac Ag Formación de complejos de ácidos nucleicos con componentes catiónicos disulfuro-reticulados para la transfección e inmunoestimulación
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
CA2808965C (en) 2010-08-20 2020-01-07 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
WO2012024629A1 (en) 2010-08-20 2012-02-23 Selecta Biosciences, Inc. Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin
AU2011293508A1 (en) 2010-08-23 2013-01-24 Selecta Biosciences, Inc. Targeted multi-epitope dosage forms for induction of an immune response to antigens
EP4066857B1 (en) 2010-08-31 2022-12-21 GlaxoSmithKline Biologicals SA Pegylated liposomes for delivery of immunogen-encoding rna
JP2013541510A (ja) 2010-08-31 2013-11-14 メルク・シャープ・エンド・ドーム・コーポレイション 新規の単一の化学物質、およびオリゴヌクレオチドの送達方法
WO2012031046A2 (en) 2010-08-31 2012-03-08 Novartis Ag Lipids suitable for liposomal delivery of protein-coding rna
PL4066819T3 (pl) * 2010-08-31 2023-06-05 Glaxosmithkline Biologicals Sa Małe liposomy do dostarczania rna kodującego immunogen
AU2011305617A1 (en) 2010-09-20 2013-02-21 Sirna Therapeutics, Inc. Novel low molecular weight cationic lipids for oligonucleotide delivery
CN103260611A (zh) 2010-09-30 2013-08-21 默沙东公司 用于寡核苷酸递送的低分子量阳离子脂质
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
US9029590B2 (en) 2010-10-21 2015-05-12 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
KR102364214B1 (ko) 2010-11-12 2022-02-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도
DK2640426T3 (en) 2010-11-16 2016-05-02 Selecta Biosciences Inc Immunostimulating Oligonucleotides
WO2012072096A1 (en) 2010-12-03 2012-06-07 Biontech Ag Method for cellular rna expression
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
US20120177701A1 (en) 2010-12-31 2012-07-12 Selecta Biosciences, Inc. Compositions comprising immunostimulatory nucleic acids and related methods
EP3202760B1 (en) 2011-01-11 2019-08-21 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
US20120189700A1 (en) 2011-01-19 2012-07-26 Zoraida Aguilar Nanoparticle Based Immunological Stimulation
US10363309B2 (en) 2011-02-04 2019-07-30 Case Western Reserve University Targeted nanoparticle conjugates
WO2012116715A1 (en) * 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
JP6054308B2 (ja) 2011-02-15 2016-12-27 メリマック ファーマシューティカルズ， インコーポレイテッドＭｅｒｒｉｍａｃｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 核酸を細胞へ送達する組成物及び方法
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
CA2828844C (en) 2011-03-02 2020-07-14 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
EP3460064B8 (en) 2011-04-03 2024-03-20 The General Hospital Corporation d/b/a Massachusetts General Hospital Efficient protein expression in vivo using modified rna (mod-rna)
EP2701734B1 (en) 2011-04-26 2019-09-25 Molecular Express, Inc. Liposomal formulations
CN103687590A (zh) 2011-04-28 2014-03-26 Stc·Unm公司 用于靶向给药的多孔纳米颗粒支撑脂双层（原始细胞）及其使用方法
WO2012158736A1 (en) 2011-05-17 2012-11-22 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof for non-human vertebrates
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
RU2670745C9 (ru) 2011-05-24 2018-12-13 Бионтех Рна Фармасьютикалс Гмбх Индивидуализированные противоопухолевые вакцины
CN103857387B (zh) 2011-06-02 2017-03-15 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法
ES2663360T3 (es) 2011-06-08 2018-04-12 Translate Bio, Inc. Lípidos escindibles
BR112013031553A2 (pt) 2011-06-08 2020-11-10 Shire Human Genetic Therapies, Inc. composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
US8916696B2 (en) 2011-06-12 2014-12-23 City Of Hope Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
CN106995488A (zh) 2011-06-20 2017-08-01 高等教育联邦系统-匹兹堡大学 计算优化的宽反应性的h1n1流感抗原
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
MX350258B (es) 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
US9008142B2 (en) 2011-07-22 2015-04-14 Insight Photonic Solutions, Inc. System and method for optimization of coherence length of tunable laser sources
US9018089B2 (en) 2011-08-30 2015-04-28 International Business Machines Corporation Multiple step anneal method and semiconductor formed by multiple step anneal
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
SI2750707T1 (sl) 2011-08-31 2019-02-28 Glaxosmithkline Biologicals Sa Pegilirani liposomi za dostavo imunogen-kodirajoče RNA
BR112014005103A2 (pt) 2011-09-02 2017-07-04 Novartis Ag composições orgânicas para tratar doenças associadas com hsf1
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013039861A2 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
EP4241785B1 (en) 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
CN103957891B (zh) 2011-09-23 2017-01-11 美利坚合众国由健康及人类服务部部长代表 基于流感血凝素蛋白的新颖疫苗
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
BR112014007852B1 (pt) 2011-10-03 2021-11-03 Moderna Therapeutics, Inc Polinucleotídeo isolado modificado e composição farmacêutica
CA2872033A1 (en) 2011-10-11 2013-04-18 Novartis Ag Recombinant self-replicating polycistronic rna molecules
PT3597644T (pt) 2011-10-18 2021-11-03 Dicerna Pharmaceuticals Inc Lípidos catiónicos de amina e suas utilizações
CA2852857A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
NZ747501A (en) 2011-10-27 2020-05-29 Massachusetts Inst Technology Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres
EP2773372B1 (en) 2011-11-03 2018-12-26 Sentinext Therapeutics SDN BHD Vaccines directed against human enteroviruses
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
JP6133883B2 (ja) 2011-11-04 2017-05-24 日東電工株式会社 薬物送達用の脂質ナノ粒子の生成方法
CN103221064B (zh) * 2011-11-23 2014-12-03 苏州工业园区唯可达生物科技有限公司 抗流感病毒的免疫方法及其组合疫苗
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
AU2012353463B2 (en) 2011-12-12 2017-08-24 Kyowa Hakko Kirin Co., Ltd. Lipid nanoparticles containing combinations of cationic lipids
TWI594767B (zh) 2011-12-12 2017-08-11 協和醱酵麒麟有限公司 含有陽離子性脂質之藥物傳遞系統用脂質奈米粒子
US20140343129A1 (en) * 2011-12-14 2014-11-20 Moderna Therapeutics, Inc. Modified nucleic acids, and acute care uses thereof
EP2791364A4 (en) 2011-12-14 2015-11-11 Moderna Therapeutics Inc PROCESS FOR RESPONSE TO A BIOLOGICAL THREAT
WO2013087083A1 (en) 2011-12-15 2013-06-20 Biontech Ag Particles comprising single stranded rna and double stranded rna for immunomodulation
PL2791160T3 (pl) * 2011-12-16 2022-06-20 Modernatx, Inc. Kompozycje zmodyfikowanego mrna
JP2015510495A (ja) 2011-12-21 2015-04-09 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 器官または器官移植片の生存可能性または寿命を延長する方法
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
JP6527331B2 (ja) 2012-03-16 2019-06-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 標的指向アミノ酸脂質
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2830991A1 (en) 2012-03-26 2015-02-04 President and Fellows of Harvard College Lipid-coated nucleic acid nanostructures of defined shape
CA2866955A1 (en) 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules
JP6211054B2 (ja) 2012-03-29 2017-10-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 脂質誘導される中性ナノ粒子
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
HK1206779A1 (en) 2012-04-02 2016-01-15 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243949A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013245950B2 (en) 2012-04-10 2016-04-21 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
DK3489220T3 (da) 2012-06-08 2021-09-06 Nitto Denko Corp Lipider til terapeutisk middel-leveringsformuleringer
CA2876155C (en) * 2012-06-08 2022-12-13 Ethris Gmbh Pulmonary delivery of mrna to non-lung target cells
CA2884870C (en) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
AU2013302526B2 (en) 2012-08-15 2018-03-22 The University Of Chicago Exosome-based therapeutics against neurodegenerative disorders
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
CN104812372A (zh) 2012-10-04 2015-07-29 约翰内斯堡金山大学 脂质体药物递送系统
AU2013337651B2 (en) 2012-11-01 2018-12-13 Factor Bioscience Inc. Methods and products for expressing proteins in cells
TW201428101A (zh) 2012-11-08 2014-07-16 Inviragen Inc 登革熱病毒血清型４型之建構物的組成物、方法及用途
AU2013343864B2 (en) 2012-11-09 2019-04-04 BioNTech SE Method for cellular RNA expression
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
WO2014089239A1 (en) 2012-12-07 2014-06-12 Alnylam Pharmaceuticals, Inc. Improved nucleic acid lipid particle formulations
EP2929035A1 (en) 2012-12-07 2015-10-14 Shire Human Genetic Therapies, Inc. Lipidic nanoparticles for mrna delivering
US20150315541A1 (en) 2012-12-13 2015-11-05 Moderna Therapeutics, Inc. Modified polynucleotides for altering cell phenotype
AU2014204826A1 (en) 2013-01-10 2015-07-09 Seqirus UK Limited Influenza virus immunogenic compositions and uses thereof
MX385338B (es) 2013-02-22 2025-03-18 CureVac SE Combinación de vacunación e inhibición de la trayectoria pd-1.
WO2014136086A1 (en) 2013-03-08 2014-09-12 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
HUE055044T2 (hu) 2013-03-14 2021-10-28 Translate Bio Inc MRNS-kódolt ellenanyagok bejuttatására szolgáló eljárások és készítmények
US20160184458A1 (en) 2013-03-14 2016-06-30 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
US20160032316A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
PT2970948T (pt) 2013-03-15 2019-03-20 Glaxosmithkline Biologicals Sa Métodos de purificação de arn
WO2014172045A1 (en) 2013-03-15 2014-10-23 The University Of British Columbia Lipid nanoparticles for transfection and related methods
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
ES2795249T3 (es) 2013-03-15 2020-11-23 Translate Bio Inc Mejora sinérgica de la administración de ácidos nucleicos a través de formulaciones mezcladas
EP2968523A4 (en) 2013-03-15 2016-07-20 Univ Pennsylvania INFLUENZA NUCLEIC ACID MOLECULES AND VACCINES MANUFACTURED THEREOF
AU2014233424B2 (en) 2013-03-15 2017-03-16 The Trustees Of The University Of Pennsylvania Vaccines with biomolecular adjuvants
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
MX376138B (es) 2013-03-28 2025-03-07 Medicago Inc Produccion de particulas similares a virus de influenza en plantas.
AR096203A1 (es) 2013-05-06 2015-12-16 Alnylam Pharmaceuticals Inc Dosificaciones y métodos para administrar moléculas de ácido nucleico formuladas en lípidos
WO2014210356A1 (en) 2013-06-26 2014-12-31 Massachusetts Institute Of Technology Multi-tailed lipids and uses thereof
TW201534578A (zh) 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd 新穎脂質
PT3019619T (pt) 2013-07-11 2021-11-11 Modernatx Inc Composições que compreendem polinucleótidos sintéticos que codificam proteínas relacionadas com crispr e sgarn sintéticos e métodos de utilização
CN105555757A (zh) 2013-07-23 2016-05-04 普洛体维生物治疗公司 用于递送信使rna的组合物和方法
WO2015013551A1 (en) 2013-07-25 2015-01-29 Marshall Christopher Patrick Conformationally stabilized rsv pre-fusion f proteins
US10398769B2 (en) 2013-08-06 2019-09-03 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
SG11201510746WA (en) 2013-08-21 2016-03-30 Curevac Ag Respiratory syncytial virus (rsv) vaccine
CN105451779A (zh) 2013-08-21 2016-03-30 库瑞瓦格股份公司 增加rna编码蛋白表达的方法
CN105473157A (zh) 2013-08-21 2016-04-06 库瑞瓦格股份公司 组合疫苗
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2927393A1 (en) 2013-10-18 2015-04-23 Moderna Therapeutics, Inc. Compositions and methods for tolerizing cellular systems
AU2014340155B2 (en) 2013-10-22 2018-11-01 Massachusetts Institute Of Technology Lipid formulations for delivery of messenger RNA
EP2883872A1 (en) 2013-12-16 2015-06-17 Universite De Bordeaux I Five-membered cyclic biscarbonates bearing amide linkages, their preparation and their uses for the preparation of polyhydroxyurethanes
WO2015095346A1 (en) 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
PL3083556T3 (pl) 2013-12-19 2020-06-29 Novartis Ag Lipidy i kompozycje lipidowe dla dostarczania środków czynnych
US10821175B2 (en) 2014-02-25 2020-11-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
ES2754239T3 (es) 2014-03-12 2020-04-16 Curevac Ag Combinación de vacunación y agonistas de OX40
US10369216B2 (en) 2014-04-01 2019-08-06 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
PL3981437T3 (pl) 2014-04-23 2025-02-24 Modernatx, Inc. Szczepionki z kwasem nukleinowym
EP3157573A4 (en) 2014-06-19 2018-02-21 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
EP3160938B1 (en) 2014-06-25 2020-09-16 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
AU2015289583A1 (en) 2014-07-16 2017-02-02 Modernatx, Inc. Chimeric polynucleotides
AU2015289573A1 (en) 2014-07-17 2017-02-02 Modernatx, Inc Terminal modifications of polynucleotides
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
IL253187B (en) 2014-12-31 2022-07-01 Us Health Novel multivalent nanoparticle-based vaccines
EP3247363A4 (en) 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
US10293058B2 (en) 2015-04-22 2019-05-21 Curevac Ag RNA containing composition for treatment of tumor diseases
WO2016176330A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
KR20180004820A (ko) 2015-05-15 2018-01-12 큐어백 아게 적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법
WO2016201377A1 (en) 2015-06-10 2016-12-15 Moderna Therapeutics, Inc. Targeted adaptive vaccines
US20180296663A1 (en) 2015-06-17 2018-10-18 Curevac Ag Vaccine composition
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
ES2937963T3 (es) * 2015-07-21 2023-04-03 Modernatx Inc Vacunas de enfermedad infecciosa
US11364292B2 (en) * 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017015457A1 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
HK1256498A1 (zh) 2015-07-30 2019-09-27 Modernatx, Inc. 聚肽表位 rna
US20190008887A1 (en) 2015-07-30 2019-01-10 ModernaTX Inc. Multimeric mrna
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
US20180237849A1 (en) 2015-08-17 2018-08-23 Modernatx, Inc. Rna mapping/fingerprinting
ES2969082T3 (es) 2015-09-17 2024-05-16 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
LT4104687T (lt) 2015-09-21 2024-02-26 Trilink Biotechnologies, Llc Kompozicijos ir būdai, skirti 5'-kepurę turinčių rnr sintetinimui
ES2810701T5 (es) 2015-10-05 2024-07-11 Modernatx Inc Procedimientos para la administración terapéutica de medicamentos de ácido ribonucleico mensajero
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
EP4349404A3 (en) * 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
MA46316A (fr) 2015-10-22 2021-03-24 Modernatx Inc Vaccin contre le cytomégalovirus humain
WO2017070620A2 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2017070618A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Cancer vaccines
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
MX2018004917A (es) 2015-10-22 2019-04-01 Modernatx Inc Vacuna de virus sincitial respiratorio.
WO2017070623A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Herpes simplex virus vaccine
MA46080A (fr) 2015-10-22 2019-07-10 Modernatx Inc Vaccins à base d'acide nucléique contre le virus varicelle-zona (vzv)
WO2017070624A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
FI3368507T3 (fi) 2015-10-28 2023-03-21 Acuitas Therapeutics Inc Uusia lipidejä ja lipidinanopartikkeliformulaatioita nukleiinihappojen annostelemiseksi
LT3386484T (lt) 2015-12-10 2022-06-10 Modernatx, Inc. Gydomųjų medžiagų sudėtis ir pristatymo metodai
WO2017106799A1 (en) 2015-12-17 2017-06-22 Modernatx, Inc. POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE
US10799463B2 (en) 2015-12-22 2020-10-13 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
US11377656B2 (en) 2016-03-10 2022-07-05 Novartis Ag Chemically modified messenger RNA's
EP4233898A3 (en) 2016-05-04 2023-11-01 CureVac SE Influenza mrna vaccines
EP3458105B1 (en) 2016-05-18 2024-01-17 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
JP7114485B2 (ja) 2016-05-18 2022-08-08 モデルナティエックス インコーポレイテッド ファブリー病の治療のためのα－ガラクトシダーゼＡをコードするポリヌクレオチド
EP3458106A4 (en) 2016-05-18 2020-03-18 Modernatx, Inc. POLYNUCLEOTIDS FOR CODING LIPOPROTEIN LIPASE FOR TREATING HYPERLIPIDEMIA
WO2017201332A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
MA45037A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polythérapie à base d'arnm pour le traitement du cancer
EP3458108A4 (en) 2016-05-18 2020-04-22 ModernaTX, Inc. POLYNUCLEOTIDES ENCODING A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
JP7088911B2 (ja) 2016-05-18 2022-06-21 モデルナティエックス インコーポレイテッド リラキシンをコードするポリヌクレオチド
SG11201809381XA (en) 2016-05-18 2018-12-28 Modernatx Inc Polynucleotides encoding interleukin-12 (il12) and uses thereof
JP7210287B2 (ja) 2016-05-18 2023-01-23 モダーナティエックス・インコーポレイテッド Ｉｉ型シトルリン血症の治療のためのシトリンをコードするポリヌクレオチド
JP2019519601A (ja) 2016-05-18 2019-07-11 モダーナティエックス・インコーポレイテッドＭｏｄｅｒｎａＴＸ， Ｉｎｃ． 急性間欠性ポルフィリン症の治療のためのポルホビリノゲン脱アミノ酵素をコードするポリヌクレオチド
US20190382774A1 (en) 2016-05-18 2019-12-19 Modernatx, Inc. Polyribonucleotides containing reduced uracil content and uses thereof
WO2017201342A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
EP3468537A1 (en) 2016-06-14 2019-04-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
JP7086870B2 (ja) 2016-06-30 2022-06-20 アルブータス・バイオファーマー・コーポレイション メッセンジャーｒｎａを送達するための組成物及び方法
AU2017326423B2 (en) 2016-09-14 2023-11-09 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
WO2018075592A1 (en) 2016-10-21 2018-04-26 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
WO2018081462A1 (en) 2016-10-26 2018-05-03 Modernatx, Inc. Methods and compositions for rna mapping
CA3042015A1 (en) 2016-10-26 2018-05-03 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
KR20190093816A (ko) 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
AU2017357758B2 (en) 2016-11-10 2023-11-16 Translate Bio, Inc. Improved process of preparing mRNA-loaded lipid nanoparticles
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
US11524066B2 (en) 2016-12-23 2022-12-13 CureVac SE Henipavirus vaccine
US20180243225A1 (en) 2017-01-25 2018-08-30 Modernatx, Inc. Ebola/marburg vaccines
CN115845040A (zh) 2017-01-27 2023-03-28 卫理公会医院 用于免疫疗法的核/壳结构平台
SG11201906969PA (en) 2017-02-01 2019-08-27 Modernatx Inc Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
WO2018144778A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Polynucleotide secondary structure
CN110505877A (zh) 2017-02-01 2019-11-26 摩登纳特斯有限公司 Rna癌症疫苗
WO2018151816A1 (en) 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
WO2018157009A1 (en) 2017-02-24 2018-08-30 Modernatx, Inc. Nucleic acid-based therapy of muscular dystrophies
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
MX2019011004A (es) 2017-03-15 2020-08-10 Modernatx Inc Compuestos y composiciones para la administracion intracelular de agentes terapeuticos.
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
US20200038499A1 (en) 2017-03-22 2020-02-06 Modernatx, Inc. Rna bacterial vaccines
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
US20200054737A1 (en) 2017-04-26 2020-02-20 Modema TX, Inc. Herpes simplex virus vaccine
WO2018232355A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna antibodies
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
WO2019018765A1 (en) 2017-07-21 2019-01-24 Modernatx, Inc. MODIFIED mRNA ENCODING PROPIONYL-COA-CARBOXYLASE AND USES THEREOF
EP3668522B1 (en) 2017-08-18 2024-09-11 ModernaTX, Inc. Efficacious mrna vaccines
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
EP3668971B8 (en) 2017-08-18 2024-05-29 ModernaTX, Inc. Rna polymerase variants
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
DK3703658T3 (da) 2017-10-31 2022-07-18 Astrazeneca Ab Lipidnanopartikler til administration af modificeret rna, der koder for et vegf-a-polypeptid
US20190192646A1 (en) 2017-11-03 2019-06-27 Modernatx, Inc. Salmonella vaccines
JP2021504445A (ja) 2017-11-21 2021-02-15 モデルナティーエックス， インコーポレイテッド エプスタイン−バーウイルスワクチン
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
AU2019293244A1 (en) 2018-06-27 2021-02-11 Modernatx, Inc. Personalized cancer vaccine epitope selection
JP2022500443A (ja) 2018-09-13 2022-01-04 モデルナティーエックス， インコーポレイテッド 進行性家族性肝内胆汁うっ滞障害を処置するための修飾ｍＲＮＡ
JP7640452B2 (ja) 2018-09-19 2025-03-05 モデルナティエックス インコーポレイテッド 高純度ｐｅｇ脂質及びそれらの使用
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
CA3113651A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
EP3876947A4 (en) 2018-11-07 2022-08-31 ModernaTX, Inc. RNA CANCER VACCINES
MX2021009245A (es) 2019-01-31 2021-11-12 Modernatx Inc Metodos de preparacion de nanoparticulas lipidicas.
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
CN113795579A (zh) 2019-02-20 2021-12-14 摩登纳特斯有限公司 用于共转录加帽的rna聚合酶变体
EP3938507A4 (en) 2019-03-11 2023-02-22 ModernaTX, Inc. PROCEDURE FOR IN VITRO FED BATCH TRANSCRIPTION
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
BR112021018526A2 (pt) 2019-03-19 2021-11-23 Arcturus Therapeutics Inc Método de fabricação de nanopartículas de rna encapsuladas em lipídio
CA3142352A1 (en) 2019-05-31 2020-12-03 Modernatx, Inc. Expanded t cell assay
BR112022002548A2 (pt) 2019-08-14 2022-06-14 Modernatx Inc Processos para purificar produtos a jusante de transcrição in vitro
WO2021050864A1 (en) 2019-09-11 2021-03-18 Modernatx, Inc. Human cytomegalovirus vaccine
JP7638972B2 (ja) 2019-09-19 2025-03-04 モデルナティエックス インコーポレイテッド 治療薬の細胞内送達のための分岐状尾部脂質化合物及び組成物
EP4031666A4 (en) 2019-09-19 2023-11-15 ModernaTX, Inc. CAP GUIDES AND THEIR USE FOR RNA MAPPING
WO2021142306A1 (en) 2020-01-10 2021-07-15 Modernatx, Inc. Variational autoencoder for biological sequence generation
US20210228707A1 (en) 2020-01-28 2021-07-29 Modernatx, Inc. Coronavirus rna vaccines
CN115103682A (zh) 2020-01-30 2022-09-23 摩登纳特斯有限公司 呼吸道病毒免疫组合物
TW202139976A (zh) 2020-01-31 2021-11-01 美商現代公司 製備脂質奈米顆粒之方法
JP7438604B2 (ja) 2020-02-07 2024-02-27 モデルナティエックス インコーポレイテッド ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン
WO2021211343A1 (en) 2020-04-13 2021-10-21 Modernatx, Inc. Zika virus mrna vaccines
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
US20230142529A1 (en) 2020-05-15 2023-05-11 Modernatx, Inc. Rna formulations for high volume distribution
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
WO2021237084A1 (en) 2020-05-21 2021-11-25 Modernatx, Inc. Methylene blue stabilized mrna compositions
US20230287437A1 (en) 2020-06-05 2023-09-14 Modernatx, Inc. Bacterial strains for dna production
AU2021320426A1 (en) 2020-08-06 2023-03-23 Modernatx, Inc. Compositions for the delivery of payload molecules to airway epithelium
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
EP4217371A1 (en) 2020-09-25 2023-08-02 ModernaTX, Inc. Multi-proline-substituted coronavirus spike protein vaccines
IL301973A (en) 2020-10-12 2023-06-01 Translate Bio Inc Improved process of preparing mrna-loaded lipid nanoparticles
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
AU2022208057A1 (en) 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
AU2022207495A1 (en) 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
IL305644A (en) 2021-03-05 2023-11-01 Modernatx Inc Vlp enteroviral vaccines
AU2022237382A1 (en) 2021-03-15 2023-09-28 Modernatx, Inc. Therapeutic use of sars-cov-2 mrna domain vaccines
EP4313072A1 (en) 2021-03-26 2024-02-07 ModernaTX, Inc. Pertussis vaccine
MX2023011400A (es) 2021-03-26 2023-10-09 Glaxosmithkline Biologicals Sa Composiciones inmunogenicas.
EP4314000A1 (en) 2021-03-31 2024-02-07 ModernaTX, Inc. Synthesis of trinucleotide and tetranucleotide caps for mrna production
US20240229109A1 (en) 2021-04-01 2024-07-11 Modernatx, Inc. Methods for identification and ratio determination of rna species in multivalent rna compositions
JP2024515035A (ja) 2021-04-01 2024-04-04 モデルナティエックス インコーポレイテッド ｍＲＮＡによる抗体構造及びアイソタイプの粘膜発現
CA3216490A1 (en) 2021-04-13 2022-10-20 Modernatx, Inc. Epstein-barr virus mrna vaccines
WO2022221335A1 (en) 2021-04-13 2022-10-20 Modernatx, Inc. Respiratory virus combination vaccines
WO2022221336A1 (en) 2021-04-13 2022-10-20 Modernatx, Inc. Respiratory syncytial virus mrna vaccines
EP4322994A1 (en) 2021-04-14 2024-02-21 ModernaTX, Inc. Influenza-coronavirus combination vaccines
TW202308658A (zh) 2021-04-23 2023-03-01 美商現代公司 異喹啉穩定之脂質奈米粒子調配物
US20220370616A1 (en) 2021-04-23 2022-11-24 Modernatx, Inc. Stabilized formulations
EP4329731A1 (en) 2021-04-29 2024-03-06 ModernaTX, Inc. Lyophilization methods for preparing lipid formulated therapeutics
IL308194A (en) 2021-05-03 2024-01-01 Pfizer Immunogenic composition against influenza
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
WO2022245888A1 (en) 2021-05-19 2022-11-24 Modernatx, Inc. Seasonal flu rna vaccines and methods of use
EP4355891A4 (en) 2021-06-14 2025-09-24 Modernatx Inc VACCINES AGAINST CORONAVIRUS GLYCOSYLATION VARIANTS
US20240285754A1 (en) 2021-06-14 2024-08-29 Modernatx, Inc. Mrna vaccines encoding flexible coronavirus spike proteins
US20240218353A1 (en) 2021-06-17 2024-07-04 Modernatx, Inc. Alternative rna purification strategies
EP4366768A4 (en) 2021-07-09 2025-05-21 ModernaTX, Inc. Pan-human coronavirus vaccines
WO2023283642A2 (en) 2021-07-09 2023-01-12 Modernatx, Inc. Pan-human coronavirus concatemeric vaccines
WO2023283645A1 (en) 2021-07-09 2023-01-12 Modernatx, Inc. Pan-human coronavirus domain vaccines
EP4381059A1 (en) 2021-08-02 2024-06-12 ModernaTX, Inc. Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
WO2023019181A1 (en) 2021-08-11 2023-02-16 Modernatx, Inc. Sars-cov-2 lipid nanoparticle vaccine formulations
WO2023018773A1 (en) 2021-08-11 2023-02-16 Modernatx, Inc. Lipid nanoparticle formulations and methods of synthesis thereof
EP4384613A1 (en) 2021-08-13 2024-06-19 ModernaTX, Inc. Multicolumn chromatography mrna purification
WO2023056401A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Rna formulations for high volume distribution, and methods of using the same for treating a disease or condition caused by or associated with human cytomegalovirus
US20250011798A1 (en) 2021-10-18 2025-01-09 Modernatx, Inc. Markerless dna production
US20250051736A1 (en) 2021-10-18 2025-02-13 Modernatx, Inc. Custom bacterial strain for recombinant protein production
WO2023069625A1 (en) 2021-10-20 2023-04-27 Modernatx, Inc. Drug product surrogate solutions
EP4423187A1 (en) 2021-10-26 2024-09-04 Exopolymer, Inc. Heat stable and/or heat activated biopolymers
EP4426855A1 (en) 2021-11-05 2024-09-11 ModernaTX, Inc. Methods of purifying dna for gene synthesis
WO2023092069A1 (en) 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use
US20250360194A1 (en) 2021-12-08 2025-11-27 Modernatx, Inc. Herpes simplex virus mrna vaccines
EP4448777A1 (en) 2021-12-15 2024-10-23 ModernaTX, Inc. Determination of encapsulation efficiency of lipid nanoparticles
US20250084397A1 (en) 2022-01-04 2025-03-13 Modernatx, Inc. Methods of purifying dna for gene synthesis
WO2023137149A1 (en) 2022-01-14 2023-07-20 Modernatx, Inc. In vitro transcription dna purification and recycling
EP4473107A1 (en) 2022-02-03 2024-12-11 ModernaTX, Inc. Continuous precipitation for mrna purification
US20250235531A1 (en) 2022-02-09 2025-07-24 Modernatx, Inc. Mucosal administration methods and formulations
WO2023196914A1 (en) 2022-04-08 2023-10-12 Modernatx, Inc. Influenza nucleic acid compositions and uses thereof
EP4508242A1 (en) 2022-04-11 2025-02-19 ModernaTX, Inc. Detection of mrna purity in a mixture
US20250250551A1 (en) 2022-04-14 2025-08-07 Modernatx, Inc. Rna polymerase variants
US20250251391A1 (en) 2022-04-15 2025-08-07 Modernatx, Inc. Ribosomal engagement potency assay
WO2023212696A1 (en) 2022-04-29 2023-11-02 Modernatx, Inc. Lyophilized human cytomegalovirus vaccines
WO2023225524A1 (en) 2022-05-17 2023-11-23 Modernatx, Inc. Preparation of highly concentrated mrna

Also Published As

Publication number Publication date
EP3981437A1 (en) 2022-04-13
US12329812B2 (en) 2025-06-17
SI4023249T1 (sl) 2025-03-31
HUE057800T2 (hu) 2022-06-28
US20160331828A1 (en) 2016-11-17
MA59052B1 (fr) 2025-01-31
SMT202500053T1 (it) 2025-03-12
ES3003986T3 (en) 2025-03-11
SMT202500052T1 (it) 2025-03-12
JP7504464B2 (ja) 2024-06-24
WO2015164674A1 (en) 2015-10-29
BR112016024644A2 (pt) 2017-10-10
EP4023249B1 (en) 2024-10-09
DK3981437T3 (da) 2025-01-13
AU2024266879A1 (en) 2024-12-12
US20240408191A1 (en) 2024-12-12
RU2016145597A3 (pl) 2018-12-07
RU2746406C2 (ru) 2021-04-13
US20210220467A1 (en) 2021-07-22
JP6881813B2 (ja) 2021-06-02
CN106659803A (zh) 2017-05-10
US20190015501A1 (en) 2019-01-17
DK3134131T3 (en) 2022-02-07
HRP20220070T1 (hr) 2022-04-01
US12274743B2 (en) 2025-04-15
AU2021203492A1 (en) 2021-06-24
RU2016145597A (ru) 2018-05-24
EP3134131B1 (en) 2021-12-22
MA58292B1 (fr) 2025-01-31
JP2024071384A (ja) 2024-05-24
CA2946751A1 (en) 2015-10-29
SG11201608798YA (en) 2016-11-29
EP4023249A1 (en) 2022-07-06
LT3981437T (lt) 2025-01-10
SG10201912038TA (en) 2020-02-27
US20240398927A9 (en) 2024-12-05
SI3134131T1 (sl) 2022-04-29
JP2021091689A (ja) 2021-06-17
US20240398931A1 (en) 2024-12-05
SI3981437T1 (sl) 2025-04-30
ES2909180T3 (es) 2022-05-05
US20220193223A1 (en) 2022-06-23
FI3981437T3 (fi) 2025-01-10
HRP20241733T1 (hr) 2025-02-28
LT3134131T (lt) 2022-02-10
HUE069802T2 (hu) 2025-04-28
US20160317647A1 (en) 2016-11-03
AU2015249553A1 (en) 2016-11-10
AU2015249553B2 (en) 2021-03-04
FI4023249T3 (fi) 2025-01-09
RU2021109685A (ru) 2021-04-13
HRP20241732T1 (hr) 2025-02-28
EP3981437B1 (en) 2024-10-09
US20190008948A1 (en) 2019-01-10
SMT202200158T1 (it) 2022-05-12
EP3134131A4 (en) 2018-06-13
US20240390480A1 (en) 2024-11-28
RS66388B1 (sr) 2025-02-28
CY1125084T1 (el) 2024-02-16
ES3009962T3 (en) 2025-03-31
RS63050B1 (sr) 2022-04-29
US20190000959A1 (en) 2019-01-03
PT3981437T (pt) 2025-01-15
PL3134131T3 (pl) 2022-04-11
LT4023249T (lt) 2025-01-10
JP2017513956A (ja) 2017-06-01
EP3134131A1 (en) 2017-03-01
EP4501318A2 (en) 2025-02-05
PT3134131T (pt) 2022-03-24
PL4023249T3 (pl) 2025-03-10
DK4023249T3 (da) 2025-01-13
PT4023249T (pt) 2025-01-14
US10022435B2 (en) 2018-07-17
CA3177878A1 (en) 2015-10-29
EP4501318A3 (en) 2025-05-14
RS66380B1 (sr) 2025-02-28
US10709779B2 (en) 2020-07-14
HUE069770T2 (hu) 2025-04-28
US9872900B2 (en) 2018-01-23

Similar Documents

Publication Publication Date Title
DK3134131T3 (en) Nucleic acid vaccines
SI3118311T1 (sl) Protismiselna nukleinska kislina
SG11201610168YA (en) Nucleic acid synthesis techniques
GB201410971D0 (en) Vaccine
GB201507119D0 (en) Nucleic Acid Construct
GB201507115D0 (en) Nucleic Acid Construct
GB201507111D0 (en) Nucleic acid construct
GB201507104D0 (en) Nucleic acid construct
GB201507108D0 (en) Nucleic acid construct
PL3185899T3 (pl) Wzmocniona szczepionka wektorowa-hvt przeciwko nd-ibd
GB201405226D0 (en) Nucleic acid preparation method
GB201408841D0 (en) Nucleic acid processing
GB201415674D0 (en) Nucleic acid analysis
PT3188755T (pt) Vacina
GB201417214D0 (en) Vaccine
GB201406628D0 (en) Vaccine
HK1235003A1 (zh) 核酸疫苗
GB201518917D0 (en) Vaccination
GB201503266D0 (en) Vaccination
GB201402630D0 (en) Nucleic acid amplification